Posted in | Nanomedicine | Nanobusiness

CombiMatrix President and CEO to Present at Health Care Conference

CombiMatrix Corporation (Nasdaq:CBMX) today announced Dr. Amit Kumar, President and CEO, will present at the Robert W. Baird + Co. 2009 Health Care Conference, which will be held at the Four Seasons Hotel New York, 57 East 57th Street, New York, NY. Dr. Kumar's presentation will take place on Wednesday, September 9, 2009, at 12:15 p.m. (Eastern).

To attend the live webcast of Dr. Kumar's presentation, please go to You may also listen to the webcast by going to CombiMatrix's website at The webcast will be archived for 90 days following the live presentation.

Baird is an employee-owned wealth management, capital markets, asset management and private equity firm with client assets of more than $66 billion. Leveraging our deep expertise and broad skills, we're dedicated to providing the best advice and service to our individual, corporate, institutional and municipal clients.

CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback